Although the incidence of and risk factors for ischemic stroke in patients with atrial fibrillation have been well studied, much less is known about the distribution, clinical features, and outcomes of extracranial systemic embolic events (SEEs) in this population. This study demonstrates that SEEs constituted at least 11.5% of clinically recognized thromboembolic events in patients with atrial fibrillation. These events are associated with high morbidity and mortality that was comparable to that of ischemic stroke. These data demonstrate that atrial fibrillation is associated with clinically important SEEs, and not merely stroke. These systemic events are not rare and merit clinical recognition because of their major impact on shortterm health outcomes and death. Recognition of SEEs is more challenging than of stroke because nonstroke ischemic clinical presentations may seem to be due to comorbid disease. It is not yet known from prospective trials whether prompt recognition and treatment of SEEs would improve clinical outcomes. This knowledge gap is best evaluated by future investigations. See p 796.
Southern Dietary Pattern Is Associated With Hazard of Acute Coronary Heart Disease in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study
The results of this study show that in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a Southern dietary pattern was associated with a significantly greater hazard of incident acute coronary heart disease. No associations with coronary heart disease were observed for the other dietary patterns derived in this population. Although these are observational data, this study was conducted in a large, population-based, and diverse sample and included a comprehensive assessment of diet and a rigorous method for deriving dietary patterns. Accordingly, this report has potential clinical impact for the practicing physician. Based on these results, it would be reasonable to make recommendations to patients to reduce intakes of the main components of the Southern dietary pattern, including added fats, fried food, eggs and egg dishes, organ meats, processed meats, and sugarsweetened beverages. There are no known risks associated with these recommendations, and they may favorably influence the hazard of acute coronary heart disease. See p 804.
A Cluster-Randomized, Controlled Trial of a Simplified Multifaceted Management Program for Individuals at High Cardiovascular Risk (SimCard Trial) in Rural Tibet, China, and Haryana, India
Cardiovascular disease is one of the leading causes of mortality and disability in China and India, not only in urban areas, but also in resource-limited rural areas. There are well-established evidence-based clinical guidelines for cardiovascular disease prevention and control. However, its uptake into clinical practice remains limited in resource-constrained, low-capacity settings. In this simplified cardiovascular management program (the Simplified Cardiovascular Management Study [SimCard] ) study, we developed and evaluated a highly simplified yet guideline-based multifaceted cardiovascular management program targeting individuals at high cardiovascular disease risk (adults ≥40 years either with existing coronary heart disease, stroke, diabetes mellitus, and/or having measured systolic blood pressure ≥160 mm Hg). The core of the program is a 2+2 model, emphasizing 2 lifestyle modifications (smoking cessation and sodium reduction) and the appropriate use of 2 effective, generally safe, and low-cost medications (antihypertensive medicine and aspirin). A customized smartphone-based Android app is developed to facilitate training of community health workers and to provide electronic decision support for them to better manage patients with high cardiovascular risk. A cluster-randomized, controlled trial was conducted in 47 rural villages in Tibet, China, and Haryana, India, with 23 randomly assigned to receive the SimCard intervention (1095 patients) and 24 control villages (991 patients) to continue usual care. The 1-year program showed that it was effective in significantly increasing medicine use and reducing systolic blood pressure, but not in changing lifestyles. The results of the SimCard trial calls for further research in evaluating its effectiveness and the applicability of this simplified primary care-based community healthcare worker-delivered model in other low-resource settings. See p 815.
High-Sensitivity Cardiac Troponin T and Risk of Hypertension
New high-sensitivity cardiac troponin T (hs-cTnT) assays can detect levels of circulating troponin that are 10 to 100 times lower than the traditional assays currently in clinical use. In addition to a possible role in ruling out acute coronary syndromes, troponin is detectable or elevated with these new high-sensitivity assays in significant proportions of otherwise healthy adults in the community, a finding that has been demonstrated in multiple studies to be a robust marker of risk for subsequent coronary heart disease events, heart failure, and death. Thus, these high-sensitivity assays hold significant promise as biomarkers of cardiac risk in preventive cardiology settings. However, the mechanism by which hs-cTnT abnormalities in individuals free of cardiovascular disease lead to subsequent events is unknown. In this setting, and given the known cross-sectional association between elevated hs-cTnT and hypertensive heart disease, we sought to evaluate whether baseline hs-cTnT is associated with incident hypertension. We found that hs-cTnT is indeed a robust marker of risk for subsequent hypertension in our study sample, even after accounting for competing deaths. Complementing this finding, baseline hs-cTnT is also strongly associated with risk for subsequent left ventricular hypertension by ECG. Taken together, these results suggest that selected people with detectable hs-cTnT Volume 132 ◼ Number 9 ◼ September 1, 2015 of squamous anal cancer and were treated with mitomycin-C alone or in association with 5-fluorouracil. The estimated annual incidence of PVOD in the French population with anal cancer was 3.9 of 1000 patients, which is much higher than the incidence of PVOD in the general population (0.5/million per year). Physicians should thus be aware of this rare complication of mitomycin-C therapy, and unexplained dyspnea in this condition should raise the possibility of underlying pulmonary vascular toxicity. In addition, intraperitoneal administration of mitomycin-C induced PVOD in rats, as demonstrated by pulmonary hypertension at right heart catheterization with major remodeling of small pulmonary veins and foci of intense microvascular endothelial-cell proliferation of the capillary bed. This was associated with a reduced pulmonary expression of GCN2, the protein coded by EIF2AK4 gene. This animal model mimicking human PVOD opens up a new area of research and represents a unique opportunity to test innovative strategies in this devastating disease. See p 834.
